Splanchnic vein thrombosis: new risk factors and management.
Splanchnic vein thrombosis (SVT) is a rather heterogeneous disease which involve one or more abdominal veins draining from different organs, including small and large bowel, liver, spleen and pancreas, and it may be associated with a wide spectrum of underlying disorders, either local or systemic. The role of new risk factors for SVT, including the JAK2 V617F mutation and the paroxysmal nocturnal hemoglobinuria clone, has been highlighted in recent years. The clinical presentations of SVT are variable and, not uncommonly, may include the concomitant presence of extensive thrombosis and gastrointestinal bleeding, thus representing a clinical challenge for treatment decisions. High quality evidence on the acute and long-term management is substantially lacking, thus requiring further research on SVT.
Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy.
Marco P
MP
Donadini
Francesco
F
Dentali
Walter
W
Ageno
D000925:Anticoagulants / Q000627:therapeutic use*; D015984:Causality; D015897:Comorbidity; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors; D012308:Risk Management; D013162:Splenic Vein; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000453:epidemiology*
D000925:Anticoagulants; D005343:Fibrinolytic Agents